News
Exothera expands range of state-of-the-art technologies by acquiring the NevoLine Upstream platform for Belgium site
Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) delivering customized process development and GMP (Good Manufacturing Practices) manufacturing services for gene therapy and viral vector-based vaccines, announces that it has acquired the NevoLine™ Upstream manufacturing platform, the...
News
The Pistoia Alliance Launches Its Enhanced President’s Startup Challenge
The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life science and healthcare R&D, has launched its revised President’s Startup Challenge. Building on the success of the previous six years, 2021 will see...
News
Prime Global and Raremark form strategic partnership to transform solutions and outcomes for patients with rare diseases
Medical communications company, Prime Global, and healthcare technology company, Raremark®, announced that they have formed a strategic partnership to transform solutions for patients with rare diseases. Together, the companies will uncover insights into the entire patient journey that will...
News
Elasmogen identifies potential vaccine candidates to fight Covid-19
Elasmogen Ltd, the pioneering biopharmaceutical company leading the development of VNAR and soloMERTM biologics, announces a significant breakthrough in the identification of next-generation protein-based drugs potentially capable of stopping Covid-19 infections. This new approach has been achieved through a...
News
Mundipharma and Cidara’s rezafungin gets Orphan Drug Designation in EU
The European Commission (EC) has adopted the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) recommendation to grant Orphan Drug Designation (ODD) to Mundipharma and Cidara Therapeutics’ rezafungin for treating invasive candidiasis (IC).
The European Commission (EC) has...
Drug Research
Humanetics receives US DoD funding for Covid-19 drug development
Humanetics has received funding from the US Department of Defense (DoD) to carry out a series of studies with its novel drug candidate, BIO 300, for Covid-19.
The US DoD researchers discovered the drug candidate to create radio-protective drugs for...
News
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab with VIR-7831
Eli Lilly and Company, Vir Biotechnology, Inc. and GlaxoSmithKline plc announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















